Tscan therapeutics to participate in the chardan 5th annual genetic medicines conference

Waltham, mass., sept. 28, 2021 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that david southwell, president and chief executive officer, will participate in a virtual fireside chat at the chardan 5th annual genetic medicines conference on tuesday, october 5, 2021 at 2:00 p.m. et.
TCRX Ratings Summary
TCRX Quant Ranking